<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099278</url>
  </required_header>
  <id_info>
    <org_study_id>00281116ZAGE</org_study_id>
    <nct_id>NCT03099278</nct_id>
  </id_info>
  <brief_title>Ezetimibe for Patients With Chronic Hepatitis D</brief_title>
  <official_title>Ezetimibe for Patients With Chronic Hepatitis D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziauddin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziauddin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and
      HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy
      with Ezetimibe may lead to decline in hepatitis D virus levels. The aim of the study is to
      evaluate the utility of Ezetimibe in patients with chronic HDV infection
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>â€¢ Decline of HDV RNA quantitative measurements of &gt;1 logs from baseline</measure>
    <time_frame>12 weeks of therapy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Hepatitis D</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 20 mg oral daily</description>
    <arm_group_label>Ezetimibe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment experienced patients; non-responders of relapsers of pegylated interferon
             therapy

          -  Age 18 years or above

          -  Presence of anti-HDV in serum

          -  Presence of quantifiable HDV RNA in serum

          -  Elevated ALT &gt; ULN

        Exclusion Criteria:

          -  Decompensated liver disease

          -  Patients with ALT levels greater than 10 times ULN (400 U/L)

          -  Pregnancy or inability to practice adequate contraception.

          -  Significant systemic or major illnesses other than liver disease, including, but not
             limited to, congestive heart failure, renal failure (eGFR&lt;50 ml/min), organ
             transplantation, serious psychiatric disease or depression and active coronary artery
             disease.

          -  Systemic immunosuppressive therapy

          -  Evidence of another form of liver disease in addition to viral hepatitis

          -  Active substance abuse, such as alcohol or injection drugs

          -  Hepatocellular carcinoma

          -  Concurrent hepatitis C infection or HIV coinfection

          -  Diagnosis of malignancy in the five years

          -  Concurrent usage of statins

          -  Concurrent use of any other drug known to inhibit NTCP

          -  Inability to understand or sign informed consent

          -  Any other condition, which in the opinion of the investigators would impede the
             patient's participation or compliance in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zaigham Abbas</last_name>
    <phone>922135862937</phone>
    <email>drzabbas@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziauddin University Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaigham Abbas</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziauddin Hospital</investigator_affiliation>
    <investigator_full_name>Zaigham Abbas</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatitis D</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>HDV RNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis D, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

